Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.50 |
| ▸ | RARB | P10826 | 5/20 | 0.45 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.44 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | THRA | P10827 | 1/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2158030 | 0.81 | CNR1 (0.52) | HSD17B1HSD17B2HPGD | |
| SCHEMBL2157847 | 0.79 | HSD17B1 (0.50) | HSD17B1HSD17B2 | |
| SCHEMBL2247695 | 0.78 | RARB (0.46) | TRPV1RARBGAAHPGD | |
| SCHEMBL2158629 | 0.76 | HSD17B1 (0.47) | HSD17B1HSD17B2HPGD | |
| SCHEMBL3809035 | 0.76 | TRPV1 (0.42) | TRPV1RARBGAAHPGD | |
| SCHEMBL2157714 | 0.76 | ACLY (0.52) | HSD17B1HSD17B2HPGD | |
| SCHEMBL2158473 | 0.74 | HSD17B2 (0.54) | HSD17B1HSD17B2GAAHPGD | |
| SCHEMBL2157643 | 0.74 | HSD17B2 (0.46) | HSD17B1HSD17B2 | |
| SCHEMBL846402 | 0.74 | TRPV1 (0.62) | TRPV1 | |
| SCHEMBL11674054 | 0.72 | TRPV1 (0.54) | TRPV1RARBGAAHPGDTHRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7985769-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-07-26 | — | — | US | disclosed |
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | VERTEX PHARMACEUTICALS (CANADA) INCORPORATED (CA) | 2006-06-29 | — | — | US | disclosed |
| US-6881741-B2 | Compounds and methods for the treatment or prevention of Flavivirus infections | VIROCHEM PHARMA INC. (CA) | 2005-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060142347-A1 | Compounds and methods for the treatment or prevention of Flavivirus infections | HAVCR2, ZC3HAV1, MAVS | TRPV1 3245/4885RARB 1559/4885HSD17B1 740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.